Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26679676 | 0.86 | ALDH1A1 (0.33) | ALDH1A1MEN1MAPTKMT2AFBP1 | |
| SCHEMBL23629645 | 0.84 | FBP1 (0.44) | ALDH1A1MEN1MAPTKMT2AFBP1 | |
| SCHEMBL25930237 | 0.83 | KDM4E (0.36) | ALDH1A1KDM4EJAK2JAK1JAK3 | |
| SCHEMBL25930266 | 0.83 | KDM4E (0.36) | ALDH1A1KDM4EJAK2JAK1JAK3 | |
| SCHEMBL28880706 | 0.81 | HDAC6 (0.35) | ALDH1A1KDM4EPKMJAK2JAK1 | |
| SCHEMBL25930787 | 0.79 | HDAC6 (0.34) | ALDH1A1KDM4EJAK2JAK1JAK3 | |
| SCHEMBL18953595 | 0.75 | KDM4E (0.41) | ALDH1A1MAPTKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL29855453 | 0.75 | KRAS (0.31) | ALDH1A1KDM4E | |
| SCHEMBL20589207 | 0.74 | CNR2 (0.42) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL29868622 | 0.73 | KDM4E (0.41) | ALDH1A1KDM4EJAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220380380-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380380-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | ALDH1A1 4659/4885MEN1 108/4885MAPT 3007/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | ALDH1A1 4659/4885MEN1 108/4885MAPT 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.